A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients
Status:
Completed
Trial end date:
2016-09-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of TVP-1012 (1 mg/day)
administered to Japanese patients with early Parkinson's disease.